BFM
CHRS icon

Boothbay Fund Management’s Coherus Oncology CHRS Stock Holding History

Boothbay Fund Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-144
Closed -$234K – 988
2020
Q1 		$234K Hold
144
– – 0.02% 629
2019
Q4 		$259K Buy
+144
New +$2.66K 0.02% 630
2019
Q3 		– Sell
-193
Closed -$427K – 779
2019
Q2 		$427K Buy
+193
New +$3.35K 0.04% 455

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Boothbay Fund Management's CHRS Position: Q1 2026 in Review

Boothbay Fund Management reduced its Coherus Oncology (CHRS) stake by 21% in Q1 2026, selling an estimated $7.11K and leaving 15,287 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Boothbay Fund Management first reported a position in CHRS in Q2 2019 and has held it in 15 quarters since. The position peaked at $761K in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Boothbay Fund Management held 15,287 shares of Coherus Oncology worth $25.8K as of Q1 2026.
  • Boothbay Fund Management sold 4,001 Coherus Oncology shares in Q1 2026, an estimated $7.11K.
  • Coherus Oncology made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1955 holding.
  • Boothbay Fund Management first reported a position in Coherus Oncology in Q2 2019 and has held it in 15 quarters since.
  • Boothbay Fund Management's Coherus Oncology position peaked at $761K in Q2 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.